Predictive levels of vascular endothelial growth factor (VEGF), thymidine kinase 1(TK1) with interleukin-6 (IL-6), plasma T cells, NK cells as well as B cells in treating diffuse large B-cell lymphoma receiving rituximab
Predictive levels of vascular endothelial growth factor (VEGF), thymidine kinase 1(TK1) with interleukin-6 (IL-6)
Abstract
Aim: To explore the effect of rituximab in combination with chemotherapy in treating diffuse large B-cell lymphoma,and levels of vascular endothelial growth factor (VEGF), thymidine kinase 1(TK1) with interleukin-6 (IL-6), plasma T cells, NK cells as well as B cells.
Methods: 80 patients admitted to Lujiang County People’s Hospital from January 2022 to January 2024 were included. The control group accepted cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy regimen. On the basis of the control group, the research group was treated with rituximab. Serum related factors. 4 mL of fasting venous blood was obtained from patients. After centrifugation, the serum was separated. The levels of vascular endothelial growth factor (VEGF), thymidine kinase 1(TK1) along with interleukin-6 (IL-6) were detected by RT-96A enzyme marker (Shenzhen Mindrays Medical Electronics Co., LTD.). The ELISA kit was purchased from Shenzhen Jingmei Biotechnology Co., LTD. Lymphocyte subsets index. Blood samples of the two groups were collected, and the plasma T cells, NK cells as well as B cells of the two groups were detected by flow cytometry.
Results: The total clinical effective rate of the research group was better relative to the control group (P<0.05). After therapy, compared to the control group, vascular endothelial growth factor, thymidine kinase 1, and interleukin-6 levels in the research group presented lower (P<0.05), plasma T cells, natural killer cells along with B cells in the research group presented lower (P<0.05), and Quality of Life Core Questionnaire-Core 30 scores in the research group presented higher (P<0.05). No difference was seen in the occurrence of adverse reactions between 2 groups (P>0.05).
Conclusion: In conclusion, Rtuximab in combination with chemotherapy patients can promote the therapeutic effect, lessen the level of serum related factors, promote the immune function, as well as promote the quality of life in patients with diffuse large B-cell lymphoma.
References
2. Wang L, Li LR, Young KH. New agents and regimens for diffuse large B cell lymphoma. J Hematol Oncol. 2020;13(1):175.
3. Friedberg JW. Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program. 2011;2011:498-505.
4. Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021;384(9):842-58.
5. Hawkes EA, Barraclough A, Sehn LH. Limited-stage diffuse large B-cell lymphoma. Blood. 2022;139(6):822-34.
6. Tong C, Zhang Y, Liu Y, Ji X, Zhang W, Guo Y, et al. Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma. Blood. 2020;136(14):1632-44.
7. Salles G, Barrett M, Foà R, Maurer J, O'Brien S, Valente N, et al. Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience. Adv Ther. 2017;34(10):2232-73.
8. Maher TM, Tudor VA, Saunders P, Gibbons MA, Fletcher SV, Denton CP, et al. Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial. Lancet Respir Med. 2023;11(1):45-54.
9. Poletto S, Novo M, Paruzzo L, Frascione PMM, Vitolo U. Treatment strategies for patients with diffuse large B-cell lymphoma. Cancer Treat Rev. 2022;110:102443.
10. Grulke N, Albani C, Bailer H. Quality of life in patients before and after haematopoietic stem cell transplantation measured with the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core Questionnaire QLQ-C30. Bone Marrow Transplant. 2012;47(4):473-82.
11. Martelli M, Ferreri AJ, Agostinelli C, Di Rocco A, Pfreundschuh M, Pileri SA. Diffuse large B-cell lymphoma. Crit Rev Oncol Hematol. 2013;87(2):146-71.
12. Tilly H, Gomes da Silva M, Vitolo U, Jack A, Meignan M, Lopez-Guillermo A, et al. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26 Suppl 5:v116-25.
13. Xu PP, Huo YJ, Zhao WL. All roads lead to targeted diffuse large B-cell lymphoma approaches. Cancer Cell. 2022;40(2):131-3.
14. Liu Y, Barta SK. Diffuse large B-cell lymphoma: 2019 update on diagnosis, risk stratification, and treatment. Am J Hematol. 2019;94(5):604-16.
15. Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A, et al. Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders. Front Immunol. 2019;10:1990.
16. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22(47):7359-68.
17. Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab. Anticancer Drugs. 2002;13 Suppl 2:S3-10.
18. Ma R, Wu D, He Z, Chang Q, Yang Y. Case Report: Complete Remission of C1q Nephropathy Treated With a Single Low-Dose Rituximab, a Reality or Coincidence? Front Pediatr. 2020;8:568773.
19. Nakamura A, Grossman S, Song K, Xega K, Zhang Y, Cvet D, et al. The SUMOylation inhibitor subasumstat potentiates rituximab activity by IFN1-dependent macrophage and NK cell stimulation. Blood. 2022;139(18):2770-81.
20. Morschhauser F, Feugier P, Flinn IW, Gasiorowski R, Greil R, Illés Á, et al. A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma. Blood. 2021;137(5):600-9.
21. On S, Chang A. Treatment of lymphoma with rituximab and chemotherapy during pregnancy. Leuk Lymphoma. 2022;63(12):2897-904.
22. Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, et al. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet. 2019;394(10216):2271-81.
23. Allen P. Diffuse Large B-Cell Lymphoma in the Elderly: Current Approaches. Curr Oncol Rep. 2020;22(11):114.
24. Svensson MC, Warfvinge CF, Fristedt R, Hedner C, Borg D, Eberhard J, et al. The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma. Oncotarget. 2017;8(42):72108-26.
25. Danilov AV, Magagnoli M, Matasar MJ. Translating the Biology of Diffuse Large B-cell Lymphoma Into Treatment. Oncologist. 2022;27(1):57-66.
26. Apte RS, Chen DS, Ferrara N. VEGF in Signaling and Disease: Beyond Discovery and Development. Cell. 2019;176(6):1248-64.
27. Li Q, Zhang L, Yang Q, Li M, Pan X, Xu J, et al. Thymidine kinase 1 drives hepatocellular carcinoma in enzyme-dependent and -independent manners. Cell Metab. 2023;35(6):912-27.e7.
28. Zhang C, Ma S, Hao X, Wang Z, Sun Z. Methylation status of TK1 correlated with immune infiltrates in prostate cancer. Front Genet. 2022;13:899384.
29. Tanaka T, Narazaki M, Kishimoto T. Interleukin (IL-6) Immunotherapy. Cold Spring Harb Perspect Biol. 2018;10(8).
30. Khan MA, Garg K, Bhurani D, Agarwal NB. Early manifestation of mild cognitive impairment in B-cell non-Hodgkin's lymphoma patients receiving CHOP and rituximab-CHOP chemotherapy. Naunyn Schmiedebergs Arch Pharmacol. 2016;389(12):1253-65.
31. Bouwstra R, He Y, de Boer J, Kooistra H, Cendrowicz E, Fehrmann RSN, et al. CD47 Expression Defines Efficacy of Rituximab with CHOP in Non-Germinal Center B-cell (Non-GCB) Diffuse Large B-cell Lymphoma Patients (DLBCL), but Not in GCB DLBCL. Cancer Immunol Res. 2019;7(10):1663-71.
32. Rummel MJ, Niederle N, Maschmeyer G, Banat GA, von Grünhagen U, Losem C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203-10.
33. Lu GQ, Zhou XH, Chen H, Tan JP. [Aidi Injection-Asisted R-CHOP Chemotherapy for the Treatment of Diffuse Large B-Cell Lymphoma]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016;24(3):733-7.
Copyright (c) 2025 Jiagui Ye
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.